Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate

PURPOSE: Reducing the dosing frequency of antipsychotics (APs) with long-acting injectables (LAIs) such as once-monthly paliperidone palmitate (PP1M) can improve adherence and clinical outcomes for schizophrenia patients. This US study compared physical and psychiatric comorbidity-related outcomes,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Drugs Real World Outcomes
Autores principales: Patel, Charmi, Emond, Bruno, Lafeuille, Marie-Hélène, Côté-Sergent, Aurélie, Lefebvre, Patrick, Tandon, Neeta, El Khoury, Antoine C.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7061019/
https://ncbi.nlm.nih.gov/pubmed/31786737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40801-019-00172-9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares